|Strategy:||Combo: Protein & vector vaccines|
|Study Type:||Phase III|
|Study Start Date:||2019-10-31|
|Study Made Public:||NA|
A multi-center, randomized, double-blind, placebo-controlled Phase 3 efficacy study of a heterologous prime/boost vaccine regimen of Ad26.Mos4.HIV and adjuvanted Clade C gp140 and mosaic gp140 to prevent HIV-1 infection among men who have sex with men and transgender women who have sex with men
HVTN 706/HPX3002 (Mosaico) is a Phase III clinical trial to evaluate efficacy of a heterologous prime/boost vaccine regimen of Ad26.Mos4.HIV and adjuvanted Clade C gp140 and mosaic gp140.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.